A clinical study of CER-1236 in solid tumors
Latest Information Update: 18 Mar 2025
At a glance
- Drugs CER-1236 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
Most Recent Events
- 13 Mar 2025 According to CERo Therapeutics media release, company anticipate conducting trials in solid tumors in 2025.
- 14 Feb 2024 According to CERo Therapeutics media release, company anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.
- 08 Jun 2023 New trial record